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Endometriosis has a significant cost of illness burden in Europe, UK and the USA, with the
majority of costs coming from reductions in productivity. However, information is scarce on if
there is a differing impact between endometriosis and other causes of chronic pelvic pain,
and if there are modifiable factors, such as pain severity, that may be significant contributors
to the overall burden.
Methods
An online survey was hosted by SurveyMonkey and the link was active between February to
April 2017. Women aged 18–45, currently living in Australia, who had either a confirmed
diagnosis of endometriosis via laparoscopy or chronic pelvic pain without a diagnosis of
endometriosis were included. The retrospective component of the WERF EndoCost tool
was used to determine direct healthcare costs, direct non-healthcare costs (carers) and indi-
rect costs due to productivity loss. Estimates were extrapolated to the Australian population
using published prevalence estimates.
Results
407 valid responses were received. The cost of illness burden was significant in women with
chronic pelvic pain (Int $16,970 to $ 20,898 per woman per year) irrespective of whether
they had a diagnosis of endometriosis. The majority of costs (75–84%) were due to produc-
tivity loss. Both absolute and relative productivity costs in Australia were higher than previ-
ous estimates based on data from Europe, UK and USA. Pain scores showed the strongest
relationship to productivity costs, a 12.5-fold increase in costs between minimal to severe
pain. The total economic burden per year in Australia in the reproductive aged population (at
10% prevalence) was 6.50 billion Int $.
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Conclusion
Similar to studies in European, British and American populations, productivity costs are the
greatest contributor to overall costs. Given pain is the most significant contributor, priority
should be given to improving pain control in women with pelvic pain
Introduction
Chronic pelvic pain (CPP) is pain in the pelvis of greater than six months duration, and is
severe enough to cause functional disability or require medical intervention [1]. Common
causes of chronic pelvic pain include endometriosis, adenomyosis, chronic infection, and
functional disorders such as irritable bowel syndrome or interstitial cystitis. Endometriosis is
the most common cause of CPP [2] with 24% to 40% of women with CPP having a diagnosis
of endometriosis [3, 4] and whilst prevalence for CPP and endometriosis are variably quoted,
all types of CPP range from 5.7% to 26.6% [5] of women. Real world estimates of endometri-
osis prevalence are between 5% [6] and 10% [7] of the reproductive aged female population.
A large multi-centre study across Europe, UK and the USA found that the total cost per
woman with endometriosis per year was €9579 with the bulk of costs (€6298) being due to
absence from work [8], with the economic burden of endometriosis being similar to or higher
than other chronic disease burdens such as heart disease and diabetes [8]. Despite the majority
of women with CPP not having a diagnosis of endometriosis [3, 4], there are few data on the
cost of illness of non-endometriosis chronic pelvic pain. The economic impact may vary sig-
nificantly between those with endometriosis and those with non-endometriosis related CPP
due to the significant surgical interventions that often occur in endometriosis [9] however
there is currently no economic analysis to support this hypothesis.
The aim of this survey and cost of illness (COI) analysis was to determine the economic
impact of both women having chronic pelvic pain either with and without a current diagnosis
of endometriosis on healthcare costs, employment related costs and other costs related to
childcare and household maintenance for women in the Australian healthcare context. Whilst
it is recognized that health and economic systems differ significantly between countries, even
within close geographical areas [10], assessing the impact to the individual and at a societal
level may help to guide policy and prioritisation for healthcare.
Methods
Survey
The WERF EndoCost tool was developed by the World Endometriosis Research Foundation
(WERF) EndoCost Consortium, and the original protocol consists of validated prospective
hospital questionnaires and both retrospective and prospective patient questionnaires [11].
Our study used the retrospective patient questionnaire component of the WERF EndoCost
tool that was modified to an Australian demographic and healthcare context and hosted on
SurveyMonkey (www.surveymonkey.com). The tool consisted of ninety-nine questions
including direct healthcare costs (e.g. costs of medications and doctors visits), direct non-
healthcare costs (e.g. transportation costs), and indirect costs of productivity loss. Total time to
complete the survey was between 30–45 minutes. Modifications were made to income and eth-
nicity to adapt to Australian norms as per the Australian Bureau of Statistics [12]. Brand
names for pharmaceuticals were modified to reflect their Australian brand names. The survey
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tool is available as S1 File. Analysis on other components of the WERF EndoCost tool (such as
time to diagnosis, pelvic pain scores etc.) will be published separately.
The survey link was distributed via the social media platforms (Facebook, Twitter and
Instagram) of Endometriosis Australia, EndoActive and Pelvic Pain Foundation of Australia.
The total combined reach of these organisations on social media was just over 35k followers.
Each organisation made two social media posts regarding the survey, the second post 3–5
weeks after the first. The survey link was active from February 2017 to April 2017, for a total of
eight weeks. Data collection was closed once there had been no new responses for five days.
Ethical approved was provided by the Western Sydney University Human Research Ethics
Committee, approval number H12019.
Women were eligible to participate in the survey if they were aged 18–45, currently living
in Australia and either had a surgically confirmed diagnosis of endometriosis, or if they had
chronic pelvic pain from any cause. Chronic pelvic pain was defined as pain in the pelvis for at
least six months that caused the woman to seek medical attention and if they had either; a lapa-
roscopy that did not show evidence of endometriosis or had not undergone a laparoscopy at
the time of survey. All data collected was from participants themselves. Following standard
practice in cost-of-illness studies, this study measured costs rather than test a specific hypothe-
sis and so no sample size calculation was necessary [11].
Health care context
In Australia, there is a mixed public and private health care system. All residents have auto-
matic access to the public system comprising: (i) primary (general practitioners (GP), allied
health and selected pharmaceuticals), and (ii) secondary care (hospital, in-patient and out-
patient). The government provides subsided care, and includes a co-payment mechanism
resulting in patient out-of-pocket costs. The purchase of private insurance does not pre-
clude using public hospitals. The assumption in this study was that patients visited public
providers.
Perspective
A ‘societal perspective’ was adopted, incorporating (i) health sector impacts, often termed
‘direct costs’, (ii) productivity impacts, often termed ‘indirect costs,’ using the human capital
approach, incorporating multiplier impact [13] and (iii) household costs (out-of-pocket costs,
and in-kind carer time costs). This was a prevalence study and estimated costs regardless of
time of diagnosis, if known.
Outcomes
The immediate aim was to estimate average per person costs, and separately, for (i) women
with a diagnosis of endometriosis, and (ii) women reported suffering from general chronic pel-
vic pain, without an associated diagnosis. The average cost per person was estimated and for
the age categories of 18–24, 25–30, 31–38 and 39+ years. Analysis was conducted by endome-
triosis and chronic pelvic pain separately. Mean and 95% confidence intervals were reported
derived using bootstrapping with 5,000 replications [14]. An a priori decision was made to
explore whether average costs differ by pain severity. The survey asked women to rate pain
from 1–10, and then was collapsed into four categories: ‘Minimal’ (1–2), ‘Mild’ (3–5), ‘Moder-
ate’ (6–8), ‘Severe’ (9–10). Women were then stratified, and the costing analysis as described
above was repeated.
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Outcomes: Extrapolation to Australian population
Results from the survey were extrapolated by multiplying: (i) estimates of the prevalence of
endometriosis using a rate of 10% [7], the most commonly accepted estimate (ii) the number
of women in each age category (iii) average costs by age-category.
Sensitivity analysis
An ‘analysis of extremes’ was conducted, where the key structural assumptions of the main
analysis were altered to generate lower bound estimates. First, the Human Capital Approach
was substituted with the Frictional Cost Approach where productivity impacts were capped at
3 months with the assumption of replacement in the workforce. Second, to account for poten-
tial uncertainty regarding unit costs estimates all estimates of costs and productivity estimates
were lowered by 10%. Third, the population prevalence of endometriosis and CPP was then
lowered to 5%.
Costs were estimated for one year and in AUD $ 2017 prices. Following standard practice,
to enable comparison of the economic burden between countries, costs were converted to
International dollars (Int $) using purchasing power parity (PPP) conversion factors so that
Int $1 is equivalent to US $1 in the United States [15]. S2 File further details the methods used.
Results
407 valid responses were received. 340 of these women had endometriosis (84%) and 67 (16%)
had chronic pelvic pain without a current diagnosis of endometriosis (hereafter referred to just
as CPP). Table 1 outlines the characteristics of the sample that were used in the costing
analysis.
The cost of illness was broken down into three categories; health related costs, productivity
costs and cost for carers. The breakdown of costs in each category is outlined in Fig 1 for endo-
metriosis and Fig 2 for CPP. Complete data for the cost breakdowns for both endometriosis
and CPP is available in S1 Table. Total health related costs were relatively stable across all age
groups and accounted for 12.5% and 19% of overall costs in endometriosis and CPP respec-
tively. No patient reached the annual out of pocket fee limit of $1,521.8. The majority of the
costs in both women with endometriosis and women with CPP were related to productivity
costs, comprising 83.6% of total costs in women with endometriosis and 75% of total costs in
women with CPP. Carer related costs were small, 3.8% of the total in women with endometri-
osis, and 5.7% in women with CPP.
For endometriosis, average per person, per year costs was estimated to be Int $ 2640 (95%
CI 2158 to 3272) for total health costs, $17484 (95% CI 16407 to 18679) for productivity costs
and $774 (95% CI 433 to 1262) for carer costs, for a total of $20,898 (95% CI 18,999 to 23,213)
for all ages combined.
For women with CPP, average per person, per year costs was estimated to be Int $ 3215
(95% CI 2528 to 4234) for total health costs, $12,789 (95% CI 10,534 to 16,068) for productivity
costs and $966 (95% CI 393 to 1499) for carer costs, for a total of $16,970 (95% CI 13,540 to
22,193) for all ages combined.
The major point of difference between the two cohorts were the social support structures;
with women with endometriosis having mostly in-kind support (87%) with regards to carers,
while women with CPP reported they did not receive any in-kind support, and all carer related
costs were paid.
Fig 3 and S2 Table outline costs by pain score in the women with endometriosis. The analy-
sis was conducted for women suffering from endometriosis only, and for all age categories
together. There were insufficient numbers to divide into age groups, or to repeat the analysis
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for chronic pelvic pain. Pain scores showed a strong relationship to overall cost ranging from
Int $ 3,805, (95% CI 1617 to 5410) in women with minimal pain to Int $ 23987, (95% CI 21492
to 26774) in women with severe pain, over a 6-fold increase between minimal pain to severe
pain. The magnitude of specific changes between minimal pain and severe pain were an
approximately 2-fold increase in health-related costs and out of pocket costs, a 12.5-fold
increase in productivity costs, and a 3-fold increase carer costs.
Table 1. Demographics of participants.
ENDOMETRIOSIS CHRONIC PELVIC PAIN P VALUE
Number Percentage Number Percentage
AGE 18–24 78 22.9% 16 23.9%
25–30 92 27.1% 15 22.4%
31–38 109 32.1% 27 40.3% 0.51
39+ 61 17.9% 9 13.4%
Total 340 100.0% 67 100.0%
PAIN SEVERITY Minimal 7 2.1% 3 4.5%
Mild 44 12.9% 11 16.4%
Moderate 87 25.6% 12 17.9% 0.22
Severe 144 42.4% 31 46.3%
Unclassified 58 17.1% 10 14.9%
WEEKLY INCOME ($AUD)
< $500 98 28.8% 16 23.9%
$501 to $1500 172 50.6% 37 55.2% 0.93
$1501 to $3000 57 16.8% 11 16.4%
$3001 to $4500 6 1.8% 0 0.0%
> $4500 2 0.6% 1 1.5%
Did not state 5 1.5% 2 3.0%
https://doi.org/10.1371/journal.pone.0223316.t001
Fig 1. Cost breakdown for women with a diagnosis of endometriosis.
https://doi.org/10.1371/journal.pone.0223316.g001
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The total female population in Australia aged between 18–45 was 4.80 million in 2017 [16],
and the total economic burden per year assuming a 10% prevalence in the reproductive aged
population was 6.50 billion Int $.
In the sensitivity analyses, where lower bound estimates were generated the economic
impacts fell substantially, as expected.
At a per person level, when a Frictional Cost Approach (FCA) was used (rather than the
Human Capital Approach) and unit costs were reduced by 10%, then average per person costs
were Int $ 8,116 (95% CI 7,056 to 8,877) for endometriosis and Int $ 8,563 (95% CI 7230 to
9765) for CPP. Regarding the population impact, if a prevalence rate of 5% (rather than 10%)
was also used, then total costs were 1.37 billion Int $.
Fig 2. Cost breakdown for women with CPP.
https://doi.org/10.1371/journal.pone.0223316.g002
Fig 3. Costs broken down by pain severity (Int $).
https://doi.org/10.1371/journal.pone.0223316.g003
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Discussion
Women in Australia with endometriosis or other causes of CPP, have a substantial financial
burden caused by their condition. We found the per person cost of endometriosis was Int
$20,898 (95% CI 18,999 to 23,213) in 2017 prices. This is higher than previous work that also
used the same tool where the estimated per person cost was Int $13,536, when converted to
2017 Int $[8]. Our study found lost productivity accounted for 83.6% of total costs in women
with endometriosis and 75% of total costs in women with CPP, compared to 66–75% [8, 17]
for women with endometriosis in previous work. We found a higher absolute and relative
impact primarily because we included the ‘multiplier impacts’ when estimating productivity.
This is an important economic consideration, with recent studies estimating these multiplier
effects are important to incorporate in cost of illness studies [13, 18]. The proportionate sample
size in this study was similar to previous reports of productivity suggesting comparability of
these data between different health jurisdictions [8, 19].
The higher cost per patient found in our study may also reflect our recruitment strategy
with participants drawn from social media engagement through major Australian endometri-
osis or pelvic pain support and advocacy groups [20]. Similar European studies [8, 17, 19]
recruited from endometriosis clinics with women in our sample reporting significantly greater
pain and work related impacts than clinic-based samples.
Importantly, the use of the WERF EndoCost tool in all of these surveys allows comparability
and increases the body of evidence in this field. Our data reported not only on women surgi-
cally confirmed with endometriosis, but also with other forms of chronic pain–some of whom
may be diagnosed with endometriosis in the future. It is important to recognize that women
will present with ‘pain’ and not with ‘endometriosis’ and whilst we move to clinical diagnosis
of endometriosis being more widely accepted[21], women will incur substantial costs no mat-
ter what their final diagnosis. Whilst there were differences in the cost of illness burden
between the two cohorts we studied, especially in regard to carer support, these were small in
terms of the absolute cost per woman per year. This is similar to previous work where pain
intensity, and resulting costs, were similar between women with CPP and those with a diagno-
sis of endometriosis [22].
Our sensitivity analyses demonstrate that the economic burden varies from $1.4 billion
(low) to $6.5 billion (high), mainly due to uncertainty regarding the true prevalence rates of
endometriosis (5% or 10%), and the form of economic valuation regarding productivity
impacts (HCA or the FCA). The HCA was used in the main analysis to represent the full
impact on women affected by the conditions and was used by Simeons in a similar study [8].
The FCA approach caps the productivity impacts at 3 months assuming that women affected
are replaced in the workforce and that the economy is no longer impacted. We know from the
survey that women who reported being employed and affected by absenteeism/presenteeism
were not actually replaced. Nonetheless, the FCA was included in the sensitivity analysis given
this is a common approach to take. It has been recommended that all COI should include the
multiplier impacts to capture the full productivity burden [18].
We chose to stratify cost of illness burden by pain, rather than ASRM disease stage, since
the relationship between disease stage and pain is very poor [23–26]. Our findings showed that
while all costs increased with increasing pain severity, productivity costs, both in percentage
and absolute dollar value, were the most significant contributor to this. Previous research
reports that women with endometriosis have greater productivity loss as pain increases [27]
with chronic pain one of the most significant contributors to absenteeism or presenteeism in
the work place [28]. Reasons for this include the difficulty that many women with CPP have
for prolonged sitting (longer than 20 minutes) [29] the necessity to attend work, despite pain,
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due to having used all available sick leave [30]. The impacts of regular absenteeism or per-
ceived low productivity can be wide ranging, with women reporting that these impacts ranged
from ‘mild’ issues such as losing a chance for promotion, to having employment terminated or
resignation due to stress [30].
Women with endometriosis report issues achieving adequate pain management [31] with
NSAIDs and hormonal treatments offering limited efficacy, having problematic side effects
[32], with discontinuation rates of between 25–50% [33]. The impact of pain reduction in
improving productivity is an important consideration. Studies showing as little as a 10%
reduction on a pain scale is needed [34] while the more generally accepted figure for chronic
pain is 30% [35]. It is likely based on this that any reduction in pain greater than 10% may play
a role in reducing productivity related costs and interventions for pain reduction should aim
for clinically meaningful reductions that impact both quality of life for the woman and
improved productivity with its benefits for both personal well-being and general productivity
[27, 36].
Strengths and limitations
Limitations of this study include the limited sample size, due in part to the in-depth nature of
the questionnaires completed and information obtained. Whilst this is the first Australian
study for endometriosis and there exist similar estimates from other countries, there are no
previous studies on CPP. We asked women to answer the endometriosis section only if they
had a histologically confirmed surgical diagnosis of endometriosis and confirmatory evidence
is not possible due to the anonymous nature of the survey. Given the significant time and effort
burden of filling in the survey (30–45 minutes) it’s unlikely that women without endometriosis
would have undertaken this but we cannot rule this out. That would place them into the CPP
group. Conversely, many women categorized as CPP may have undiagnosed endometriosis.
Previous work suggests that the diagnosis of endometriosis may range from 33% [37] to 75%
[38]. Importantly our study demonstrates a similar economic burden no matter which is the
final diagnosis of CPP, and the key point is that both endometriosis and other forms of CPP
result in substantial personal and societal economic impact.
Over 43% of participants had pain in the most severe range and without population level
data on pain distribution, we cannot determine how representative our sample is of the larger
endometriosis/CPP population and these data may over-represent those not responding well
to medical or surgical management. We did not collect data on geographical location of
respondents, so it is possible that our sample did not represent potential differences in the cost
of illness that may exist between women in urban, rural and remote areas. However, based on
our previous work in this population using the same recruitment strategies [39] we expect that
both urban and rural women are well represented in this sample. Women in our survey
reported an income in the $501–1500 AUD bracket—in line with the $1448AUD average
weekly income (adjusted for the 0.89 gender pay gap) earned by adult Australian women in
2017 [40]. Finally, presenteeism and pain scores were estimated using a 7-day recall in keeping
with the EndoCost tool. We recognize that pelvic pain scores, and by association presenteeism,
fluctuate substantially during the month, often dependent on the phase of the menstrual cycle.
Given the sample size it is likely that overall pain scores were represented at various stages of
women’s menstrual cycles, and that the estimate for the population overall is representative of
this cohort of sufferers. It is likely that the estimated health sector costs are an underestimate.
The ENDCOST tool did not distinguish whether women accessed public or private care. The
analysis assumed that all women used the public health system. All women would have used
Medicare funded primary care, however this is unlikely for secondary care. Approximately
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60% of adults over 18 years have a form of private insurance for secondary care[41], however it
is unknown what percentage of women with endometriosis have insurance, whether this
would cover relevant treatments and procedures, and the unit costs of private care are also not
routinely available. Overall, the analysis is conservative.
Conclusion
This research clarifies that endometriosis and chronic pelvic pain have considerable impact for
the women affected; the health sector; the wider economy and to carers. Given the huge finan-
cial burden of endometriosis and CPP, there is an urgent need for accurate epidemiological
studies to assess the true prevalence rate of endometriosis, and for substantive longitudinal
studies that determine these economic impacts with greater accuracy to guide policy at a
national and international level. The inclusion of economic evaluations alongside future inter-
vention studies to assess cost effectiveness, will allow a greater understanding of how the eco-
nomic burden is reduced, including improvements in quality of life for women suffering with
endometriosis and other forms of CPP.
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